NRx Pharmaceuticals appoints Seth Van Voorhees as CFO and Treasurer, effective June 13, 2022

NRX Pharmaceuticals, Inc.

Van Voorhees most recently CFO of PDS Biotechnology; prior CFO at Research Frontiers and American Pacific.
Employment agreement: $400k annual base salary, $200k target bonus, and option grant for 325,000 shares with two-year vesting.
Severance: nine months' salary plus prorated bonus and accelerated vesting on termination without cause or change of control.
Company focusing resources on psychiatry franchise, particularly NRX-101 for bipolar depression with suicidality.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Seth Van Voorhees

Chief Financial Officer and Treasurer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2022-06-13
Filed: June 8, 2022, 7:59 PM ET

On June 6, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Seth Van Voorhees, 61, to serve as Chief Financial Officer (“CFO”) and Treasurer of the Company, effective June 13, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Seth Van Voorhees was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

On June 6, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Seth Van Voorhees, 61, to serve as Chief Financial Officer (“CFO”) and Treasurer of the Company, effective June 13, 2022.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-001844

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.